DBW

"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"

"This investment is a strong endorsement of our team, technology, and vision. The early clinical data from our temporary device has given us real momentum, and with this funding, we’re excited to advance our permanent pacing platform, an innovation that could redefine how heart failure is treated."